Osteoarthritis Drugs Market Outlook:
Osteoarthritis Drugs Market size was over USD 10.43 billion in 2025 and is poised to exceed USD 22.52 billion by 2035, witnessing over 8% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of osteoarthritis drugs is evaluated at USD 11.18 billion.
The rising prevalence of osteoarthritis is augmenting a high demand for advanced medications. Several factors such as genetics, injury, pre-existing joint disease, and obesity contribute to osteoarthritis growth. For instance, according to the World Health Organization (WHO) report, around 70% of people living with osteoarthritis are over 55 years of age. Furthermore, the Institute of Health Metrics and Evaluation estimates that by 2050, around 1 billion people are expected to have osteoarthritis. Presetly, over 15% of people above 30 years of age are experiencing osteoarthritis issues. Thus, as the prevalence of osteoarthritis is increasing, the demand for modern therapeutics including drugs is set to boom.
Many players in the osteoarthritis drugs market are investing heavily in R&D for the production of advanced and effective drug formulations. Such moves are expanding their pharmaceutical product offerings, and maximizing revenue shares, leading to an uplift in their position in the competitive space. For instance, Sanofi SA’s Third Quarter 2024 report reveals that the pharma sales in Q3 2024 reached USD 8842 million. Also, the pharma segment of the company accounted for 62.2% of total biopharma sales.
